The Cancer Telethon’s slogan has always been “People you know helping people you know.” While we all know someone with cancer ...

Here are some of the stocks making headlines in midday trading. Oracle — Shares of the cloud platform provider popped more ...

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a ...

Jodi McNamara has learned a lot of tricks — and sheer determination — help her fight insurance to get her husband the best ...

Revolution Medicines 'unprecedented' cancer trial data, Allogene's off-the-shelf CAR-T, and other biotech news ...

The new data bolster Allogene’s efforts to develop a new, easily administered cell therapy that could delay or prevent cancer recurrence.

Precision Medicine Online's seventh annual survey shows precision oncology programs didn't go unscathed as the Trump administration slashed research funding and canceled projects.

Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD ...

Allogene Therapeutics’ gamble on a never-before-seen trial strategy seems to be paying off, with the biotech’s off-the-shelf cell therapy eradicating residual lymphoma in over half of evaluated pat | ...

Allogene Therapeutics said on Monday that interim data from a mid-stage study showed its experimental off-the-shelf CAR-T therapy reduced the risk of cancer relapse ​in patients with blood cancer.

Mary Bird Perkins Cancer Center in Baton Rouge, Louisiana is offering a CAR-T cell-based immunotherapy, which genetically ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...